All Stories

  1. Introducing FREMML: a decision-support approach for automated identification of individuals at high imminent fracture risk

    Article • Archives of Osteoporosis, November 2025, Springer Science + Business Media

    Bo Abrahamsen

  2. The Danish Nationwide Osteoporosis Cohort Trials Environment (NOCTE) – a DXA dataset for the 1900-1960 birth cohort

    Article • Journal of Clinical Densitometry, November 2025, Elsevier

    Bo Abrahamsen

  3. An enhanced fracture risk evaluation model (FREM) using national health data on morbidity and medications

    Article • Journal of Bone and Mineral Research, October 2025, Oxford University Press (OUP)

    Bo Abrahamsen

  4. Surgical treatment of hyperparathyroidism

    Article • Ugeskrift for Læger, October 2025, Danish Medical Association

    Bo Abrahamsen

  5. Early life determinants of skeletal maturation, body composition and endocrine health in young adults (EPIPEAK): protocol for a nationwide birth cohort study

    Article • BMJ Open, October 2025, BMJ

    Bo Abrahamsen

  6. Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement

    Article • Endocrine Practice, May 2025, Elsevier

    Bo Abrahamsen

  7. Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE

    Article • Osteoporosis International, February 2025, Springer Science + Business Media

    Bo Abrahamsen

  8. Prediction of imminent osteoporotic fracture risk in Danish postmenopausal women—can the addition of self-reported clinical risk factors improve the prediction of the register-based FREM algorithm?

    Article • Archives of Osteoporosis, February 2025, Springer Science + Business Media

    Bo Abrahamsen

  9. Biological Heterogeneity in Susceptibility to Glucocorticoid-Induced Bone Loss: Short- and Long-Term Hip BMD Trajectories

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2024, Endocrine Society

    Bo Abrahamsen

  10. Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk

    Article • Osteoporosis International, July 2024, Springer Science + Business Media

    Dr Patricia Khashayar, Bo Abrahamsen

  11. Multimorbidity clusters potentially superior to individual diseases for stratifying fracture risk in older people: a nationwide cohort study

    Article • Age and Ageing, July 2024, Oxford University Press (OUP)

    Bo Abrahamsen

  12. Treating osteoporosis in the oldest old

    Article • Journal of Bone and Mineral Research, May 2024, Oxford University Press (OUP)

    Bo Abrahamsen

  13. Ten-year follow-up of fracture risk in a systematic population-based screening program: the risk-stratified osteoporosis strategy evaluation (ROSE) randomised trial

    Article • EClinicalMedicine, May 2024, Elsevier

    Bo Abrahamsen

  14. Sustained hypophosphatemia after denosumab in a patient on hemodialysis

    Article • Bone, April 2024, Elsevier

    Bo Abrahamsen

  15. Validity of Major Osteoporotic Fracture Diagnoses in the Danish National Patient Registry

    Article • Clinical Epidemiology, April 2024, Taylor & Francis

    Bo Abrahamsen

  16. Evidence-Based Guideline for the management of osteoporosis in men

    Article • Nature Reviews Rheumatology, March 2024, Springer Science + Business Media

    Bo Abrahamsen

  17. Opportunistically identifiable vertebral fractures on routine radiological imaging predict mortality: observational cohort study

    Article • Osteoporosis International, January 2024, Springer Science + Business Media

    Bo Abrahamsen

  18. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2024, Endocrine Society

    Bo Abrahamsen

  19. Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2024, Endocrine Society

    Bo Abrahamsen

  20. Digital solutions for decision support in general practice – a rapid review focused on systems developed for the universal healthcare setting in Denmark

    Article • BMC Primary Care, December 2023, Springer Science + Business Media

    Bo Abrahamsen

  21. Towards Improved Identification of Vertebral Fractures in Routine Computed Tomography (CT) Scans: Development and External Validation of a Machine Learning Algorithm

    Article • Journal of Bone and Mineral Research, December 2023, Oxford University Press (OUP)

    Bo Abrahamsen

  22. Epidemiology of Tumor-Induced Osteomalacia in Germany Based on Real World Data

    Article • Calcified Tissue International, November 2023, Springer Science + Business Media

    Bo Abrahamsen

  23. Excess mortality following a first and subsequent osteoporotic fracture: a Danish nationwide register-based cohort study on the mediating effects of comorbidities

    Article • RMD Open, November 2023, BMJ

    Bo Abrahamsen

  24. Biological heterogeneity in skeletal susceptibility to glucocorticoid induced bone loss: Short- and long-term BMD trajectories during unopposed GC treatment in adults

    Article • Endocrine Abstracts, October 2023, Bioscientifica

    Bo Abrahamsen

  25. An enhanced version of FREM (Fracture Risk Evaluation Model) using national administrative health data: analysis protocol for development and validation of a multivariable prediction model

    Article • Diagnostic and Prognostic Research, October 2023, Springer Science + Business Media

    Bo Abrahamsen

  26. Healthcare costs associated with opportunistically identifiable vertebral fractures

    Article • Bone, October 2023, Elsevier

    Bo Abrahamsen

  27. Explaining declining hip fracture rates in Norway: a population-based modelling study

    Article • The Lancet Regional Health - Europe, July 2023, Elsevier

    Bo Abrahamsen

  28. ‘Skeletal Age’ for mapping the impact of fracture on mortality

    Article • eLife, May 2023, eLife

    Bo Abrahamsen

  29. New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral Fractures

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2023, Endocrine Society

    Bo Abrahamsen

  30. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

    Article • BMJ, May 2023, BMJ

    Bo Abrahamsen

  31. Fracture Risk in Men and Women With Vertebral Fractures Identified Opportunistically on Routine Computed Tomography Scans and Not Treated for Osteoporosis: An Observational Cohort Study

    Article • JBMR Plus, March 2023, Oxford University Press (OUP)

    Bo Abrahamsen

  32. Epidemiological Factors Associated with Prescription of Opioids for Chronic Non-Cancer Pain in Adults: A Country-Wide, Registry-Based Study in Denmark Spans 2004–2018

    Article • Journal of Pain Research, February 2023, Taylor & Francis

    Bo Abrahamsen

  33. Primary hyperparathyroidism and fracture probability

    Article • Osteoporosis International, December 2022, Springer Science + Business Media

    Bo Abrahamsen

  34. Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia

    Article • Journal of Internal Medicine, December 2022, Wiley

    Bo Abrahamsen

  35. Association of Multimorbidity and Excess Mortality After Fractures Among Danish Adults

    Article • JAMA Network Open, October 2022, American Medical Association (AMA)

    Bo Abrahamsen

  36. Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group

    Article • Archives of Osteoporosis, June 2022, Springer Science + Business Media

    Dr Patricia Khashayar, Bo Abrahamsen

  37. Osteoporosis epidemiology using international cohorts

    Article • Current Opinion in Rheumatology, June 2022, Wolters Kluwer Health

    Bo Abrahamsen

  38. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study

    Article • Osteoporosis International, June 2022, Springer Science + Business Media

    Bo Abrahamsen

  39. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies

    Article • JBMR Plus, May 2022, Oxford University Press (OUP)

    Bo Abrahamsen

  40. Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation)

    Article • Bone, May 2022, Elsevier

    Bo Abrahamsen

  41. Mild vertebral fractures – do they matter?

    Article • Bone Reports, May 2022, Elsevier

    Bo Abrahamsen

  42. Opportunistically identified vertebral fractures and imminent fracture risk: Observational cohort study in 2,000 men and women with routine CT of chest and/or abdomen

    Article • Bone Reports, May 2022, Elsevier

    Bo Abrahamsen

  43. Opportunistically identified vertebral fractures on routine CT scans are predictive of increased mortality: Observational cohort study

    Article • Bone Reports, May 2022, Elsevier

    Bo Abrahamsen

  44. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case-reports

    Article • Bone Reports, May 2022, Elsevier

    Bo Abrahamsen

  45. Real-world data of bone turnover markers to monitor oral bisphosphonate treatment

    Article • Bone Reports, May 2022, Elsevier

    Bo Abrahamsen

  46. Regulation of bone mass in endocrine diseases including diabetes

    Article • Best Practice & Research Clinical Endocrinology & Metabolism, March 2022, Elsevier

    Bo Abrahamsen

  47. FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study

    Article • Osteoporosis International, February 2022, Springer Science + Business Media

    Bo Abrahamsen

  48. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database

    Article • Osteoporosis International, February 2022, Springer Science + Business Media

    Bo Abrahamsen

  49. The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study

    Article • BMC Endocrine Disorders, January 2022, Springer Science + Business Media

    Bo Abrahamsen

  50. Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review

    Article • Calcified Tissue International, January 2022, Springer Science + Business Media

    Bo Abrahamsen

  51. Fractures following pregnancy in Osteogenesis imperfecta – A self-controlled case series using Danish Health Registers

    Article • Bone, January 2022, Elsevier

    Bo Abrahamsen

  52. Osteoarthritis in osteogenesis imperfecta: A nationwide register-based cohort study

    Article • Bone, January 2022, Elsevier

    Bo Abrahamsen

  53. Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A Danish national cohort study

    Article • Bone, December 2021, Elsevier

    Bo Abrahamsen

  54. Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models

    Article • Journal of Bone and Mineral Research, November 2021, Oxford University Press (OUP)

    Bo Abrahamsen

  55. Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM)

    Article • Osteoporosis International, October 2021, Springer Science + Business Media

    Bo Abrahamsen

  56. Accelerated osteoarthritis in women with polycystic ovary syndrome: a prospective nationwide registry-based cohort study

    Article • Arthritis Research & Therapy, August 2021, Springer Science + Business Media

    Bo Abrahamsen

  57. One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data

    Article • Osteoporosis International, August 2021, Springer Science + Business Media

    Bo Abrahamsen

  58. Assessing Health Consequences of Vitamin D Fortification Utilizing a Societal Experiment Design: Methodological Lessons Learned from the D-Tect Project

    Article • International Journal of Environmental Research and Public Health, July 2021, MDPI AG

    Bo Abrahamsen

  59. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies

    Article • JBMR Plus, June 2021, Oxford University Press (OUP)

    Bo Abrahamsen

  60. Validation of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data

    Article • Bone, June 2021, Elsevier

    Bo Abrahamsen

  61. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease

    Article • Endocrine, May 2021, Springer Science + Business Media

    Bo Abrahamsen

  62. Epidemiology of Tumor-Induced Osteomalacia in Denmark

    Article • Calcified Tissue International, April 2021, Springer Science + Business Media

    Bo Abrahamsen

  63. Analysis of disparity in hip fracture rates between the five Danish healthcare regions 2014-2018

    Article • Bone Reports, April 2021, Elsevier

    Bo Abrahamsen

  64. Pregnancy-associated fracture risk in women with osteogenesis imperfecta, a nationwide register-based SCCS

    Article • Bone Reports, April 2021, Elsevier

    Bo Abrahamsen

  65. The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications

    Article • Osteoporosis International, March 2021, Springer Science + Business Media

    Bo Abrahamsen

  66. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

    Article • Health Technology Assessment, March 2021, National Institute for Health Research

    Bo Abrahamsen

  67. Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?

    Article • Current Osteoporosis Reports, February 2021, Springer Science + Business Media

    Bo Abrahamsen

  68. Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway

    Article • Osteoporosis International, January 2021, Springer Science + Business Media

    Bo Abrahamsen

  69. A comparison of fracture risk assessment tools

    Article • January 2021, Elsevier

    Bo Abrahamsen

  70. Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis

    Article • Journal of Bone and Mineral Research, December 2020, Oxford University Press (OUP)

    Bo Abrahamsen

  71. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports

    Article • Journal of Bone and Mineral Research, December 2020, Oxford University Press (OUP)

    Bo Abrahamsen

  72. Response to Shao Et Al.

    Article • Journal of Bone and Mineral Research, December 2020, Oxford University Press (OUP)

    Bo Abrahamsen

  73. Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2020, Endocrine Society

    Bo Abrahamsen

  74. Rheumatoid arthritis treatment associated changes in circulating bone-turnover markers

    Article • Bone Reports, October 2020, Elsevier

    Bo Abrahamsen

  75. The effectiveness of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures: A register-based cohort study

    Article • Bone Reports, October 2020, Elsevier

    Bo Abrahamsen

  76. The potential for opportunistic identification of vertebral fractures in patients undergoing a CT scan as part of daily clinical practice: Descriptive study using registry data

    Article • Bone Reports, October 2020, Elsevier

    Bo Abrahamsen

  77. Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies

    Article • Nutrients, September 2020, MDPI AG

    Bo Abrahamsen

  78. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials

    Article • Journal of Bone and Mineral Research, August 2020, Oxford University Press (OUP)

    Bo Abrahamsen

  79. The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers

    Article • Bone, August 2020, Elsevier

    Bo Abrahamsen

  80. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2020, Endocrine Society

    Bo Abrahamsen

  81. Hiding in plain sight—unreported osteoporotic vertebral fractures

    Article • European Radiology, May 2020, Springer Science + Business Media

    Bo Abrahamsen

  82. Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom

    Article • Osteoporosis International, March 2020, Springer Science + Business Media

    Bo Abrahamsen

  83. Assessment of fracture risk in women with eating disorders: The utility of dual‐energy x‐ray absorptiometry (DXA)—Clinical cohort study

    Article • International Journal of Eating Disorders, February 2020, Wiley

    Bo Abrahamsen

  84. Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries

    Article • Bone, February 2020, Elsevier

    Bo Abrahamsen

  85. Oral bisphosphonate use and all‐cause mortality in patients with moderate‐severe (grade 3B‐5D) chronic kidney disease: a population‐based cohort study

    Article • Journal of Bone and Mineral Research, January 2020, Wiley

    Bo Abrahamsen

  86. Fractures in women with eating disorders—Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls

    Article • International Journal of Eating Disorders, January 2020, Wiley

    Bo Abrahamsen

  87. Age at hip fracture and life expectancy in Denmark – Secular trends over two decades

    Article • Bone, January 2020, Elsevier

    Bo Abrahamsen

  88. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2019, Endocrine Society

    Bo Abrahamsen

  89. Proton pump inhibitors and fracture risk. The HUNT study, Norway

    Article • Osteoporosis International, November 2019, Springer Science + Business Media

    Bo Abrahamsen

  90. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

    Article • Journal of the American College of Cardiology, October 2019, Elsevier

    Bo Abrahamsen

  91. Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study

    Article • Endocrine Connections, October 2019, Bioscientifica

    Bo Abrahamsen

  92. The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes

    Article • Calcified Tissue International, September 2019, Springer Science + Business Media

    Bo Abrahamsen

  93. Tramadol prescribed use in general and chronic noncancer pain: a nationwide register-based cohort study of all patients above 16 years

    Article • Scandinavian Journal of Pain, September 2019, De Gruyter

    Bo Abrahamsen

  94. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskele...

    Article • Osteoporosis International, August 2019, Springer Science + Business Media

    Bo Abrahamsen

  95. Fracture risk following intermission of osteoporosis therapy

    Article • Osteoporosis International, June 2019, Springer Science + Business Media

    Bo Abrahamsen

  96. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk

    Article • European Journal of Endocrinology, June 2019, Bioscientifica

    Bo Abrahamsen

  97. SaO028BONE FRACTURES IN PATIENTS ON RENAL REPLACEMENT THERAPY: DOES DIABETES INCREASE THE RISK?

    Article • Nephrology Dialysis Transplantation, June 2019, Oxford University Press (OUP)

    Bo Abrahamsen

  98. Excess mortality following hip fracture in patients with diabetes according to age: a nationwide population-based cohort study of 154,047 hip fracture patients

    Article • Age and Ageing, May 2019, Oxford University Press (OUP)

    Bo Abrahamsen

  99. Lack of Transparency in the Meta-Analyses of Dietary and Urinary Sodium and Bone Mineral Density or Risk of Osteoporosis: A Letter to the Journal

    Article • Journal of the American College of Nutrition, April 2019, Taylor & Francis

    Sofus Larsen, Bo Abrahamsen, Joanna Michalowska

  100. Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016

    Article • Bone, March 2019, Elsevier

    Bo Abrahamsen

  101. Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients

    Article • Hip International, March 2019, SAGE Publications

    Bo Abrahamsen

  102. Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk

    Article • Thyroid, March 2019, Mary Ann Liebert Inc

    Bo Abrahamsen

  103. Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy

    Article • Scandinavian Journal of Urology, February 2019, Taylor & Francis

    Bo Abrahamsen, Lars Lund

  104. Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank

    Article • Aging Clinical and Experimental Research, February 2019, Springer Science + Business Media

    Bo Abrahamsen

  105. Osteoporosis; Prevention and Ca—Vitamin D Treatment

    Article • January 2019, Elsevier

    Bo Abrahamsen

  106. Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study

    Article • Acta Obstetricia Et Gynecologica Scandinavica, December 2018, Wiley

    Bo Abrahamsen

  107. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention

    Article • Bone, December 2018, Elsevier

    Bo Abrahamsen

  108. Does bisphosphonate treatment reduce the risk of future cancer?

    Article • Chinese Clinical Oncology, December 2018, AME Publishing Company

    Bo Abrahamsen

  109. Side effects of drugs for osteoporosis and metastatic bone disease

    Article • British Journal of Clinical Pharmacology, October 2018, Wiley

    Bo Abrahamsen

  110. VITAMIN D supplementation for musculoskeletal Health outcomes in adults – THE END OF THE BEGINNING?

    Article • Maturitas, October 2018, Elsevier

    Bo Abrahamsen

  111. PMS71 - SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE: A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK.

    Article • Value in Health, October 2018, Elsevier

    Bo Abrahamsen

  112. Adverse Effects of Drugs for Osteoporosis

    Article • September 2018, Wiley

    Bo Abrahamsen

  113. Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report

    Article • Journal of Medical Case Reports, September 2018, Springer Science + Business Media

    Bo Abrahamsen, Peter Schwarz

  114. High calcium intake in men not women is associated with all-cause mortality risk: Melbourne Collaborative Cohort Study

    Article • Archives of Osteoporosis, September 2018, Springer Science + Business Media

    Bo Abrahamsen

  115. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management

    Article • Endocrine Reviews, August 2018, Endocrine Society

    Bo Abrahamsen

  116. A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries

    Article • Journal of Bone and Mineral Research, August 2018, Wiley

    Bo Abrahamsen

  117. Diagnosis and management of bone fragility in diabetes: an emerging challenge

    Article • Osteoporosis International, July 2018, Springer Science + Business Media

    Bo Abrahamsen

  118. Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2018, Endocrine Society

    Bo Abrahamsen

  119. Social inequality and fractures—secular trends in the Danish population: a case-control study

    Article • Osteoporosis International, June 2018, Springer Science + Business Media

    Bo Abrahamsen

  120. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway

    Article • Osteoporosis International, May 2018, Springer Science + Business Media

    Bo Abrahamsen

  121. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Article • Thyroid, May 2018, Mary Ann Liebert Inc

    Bo Abrahamsen

  122. The Changing Role of Patient Education in Osteoporosis

    Article • Journal of Bone and Mineral Research, April 2018, Wiley

    Bo Abrahamsen

  123. Prevalence and incidence of clinically diagnosed knee, hip and hand osteoarthritis in women with polycystic ovary syndrome: a National Register-Based Study

    Article • Osteoarthritis and Cartilage, April 2018, Elsevier

    Bo Abrahamsen

  124. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome

    Article • Cardiovascular Diabetology, March 2018, Springer Science + Business Media

    Bo Abrahamsen

  125. Lactose avoidance and bone

    Article • Maturitas, March 2018, Elsevier

    Bo Abrahamsen

  126. The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old

    Article • Journal of Internal Medicine, November 2017, Wiley

    Bo Abrahamsen

  127. Response to letter: Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2017, Endocrine Society

    Bo Abrahamsen

  128. Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors

    Article • European Geriatric Medicine, November 2017, Elsevier

    Bo Abrahamsen, Peter Schwarz

  129. Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture—limitations and scope for fracture liaison services in prevention of hip fracture

    Article • Osteoporosis International, September 2017, Springer Science + Business Media

    Bo Abrahamsen

  130. Bespoke or one size fits all—Vitamin D fortification, targeted supplementation in risk groups or individual measurement?

    Article • Maturitas, September 2017, Elsevier

    Bo Abrahamsen

  131. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review

    Article • Rhinology Journal, September 2017, Rhinology

    Bo Abrahamsen

  132. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2017, Endocrine Society

    Bo Abrahamsen, Professor Marianne Andersen

  133. Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting

    Article • Osteoporosis International, August 2017, Springer Science + Business Media

    Bo Abrahamsen

  134. Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study

    Article • Osteoporosis International, July 2017, Springer Science + Business Media

    Bo Abrahamsen

  135. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway

    Article • Osteoporosis International, July 2017, Springer Science + Business Media

    Bo Abrahamsen

  136. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users

    Article • Osteoporosis International, June 2017, Springer Science + Business Media

    Bo Abrahamsen

  137. Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-tect study, a population-based case-cohort study

    Article • American Journal of Clinical Nutrition, May 2017, American Society for Nutrition

    Bo Abrahamsen

  138. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting

    Article • Osteoporosis International, April 2017, Springer Science + Business Media

    Bo Abrahamsen

  139. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2017, Endocrine Society

    Bo Abrahamsen

  140. The calcium and vitamin D controversy

    Article • Therapeutic Advances in Musculoskeletal Disease, March 2017, SAGE Publications

    Bo Abrahamsen

  141. Women’s lived experiences of learning to live with osteoporosis: a longitudinal qualitative study

    Article • BMC Women s Health, March 2017, Springer Science + Business Media

    Bo Abrahamsen

  142. Prenatal exposure to vitamin D from fortified margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the D-tect observational study

    Article • British Journal Of Nutrition, March 2017, Cambridge University Press

    Bo Abrahamsen

  143. Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients

    Article • Calcified Tissue International, February 2017, Springer Science + Business Media

    Bo Abrahamsen

  144. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

    Article • Osteoporosis International, January 2017, Springer Science + Business Media

    Bo Abrahamsen

  145. Abstracts

    Article • European Thyroid Journal, January 2017, Karger Publishers

    Bo Abrahamsen

  146. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review

    Article • Rhinology Journal, January 2017, Rhinology

    Bo Abrahamsen

  147. Cardiovascular disease in patients with osteogenesis imperfecta — a nationwide, register-based cohort study

    Article • International Journal of Cardiology, December 2016, Elsevier

    Bo Abrahamsen

  148. Diagnostic devices for osteoporosis in the general population: A systematic review

    Article • Bone, November 2016, Elsevier

    Bo Abrahamsen

  149. Mechanisms of diabetes mellitus-induced bone fragility

    Article • Nature Reviews Endocrinology, September 2016, Springer Science + Business Media

    Bo Abrahamsen

  150. Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects

    Article • Osteoporosis International, September 2016, Springer Science + Business Media

    Bo Abrahamsen, Mr Bjorn E Rosengren

  151. Maternal serum retinol and  -carotene concentrations and neonatal bone mineralization: results from the Southampton Womens Survey cohort

    Article • American Journal of Clinical Nutrition, September 2016, American Society for Nutrition

    Bo Abrahamsen

  152. Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study

    Article • Journal of Bone and Mineral Research, August 2016, Wiley

    Bo Abrahamsen

  153. Reply to: systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women

    Article • International Journal of Rheumatic Diseases, August 2016, Wiley

    Bo Abrahamsen

  154. Epidemiology of Fractures in Diabetes

    Article • Calcified Tissue International, July 2016, Springer Science + Business Media

    Bo Abrahamsen

  155. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study

    Article • Journal of Bone and Mineral Research, July 2016, Wiley

    Bo Abrahamsen

  156. Proton pump inhibitors and osteoporosis

    Article • Current Opinion in Rheumatology, July 2016, Wolters Kluwer Health

    Bo Abrahamsen

  157. Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?

    Article • Annals of the New York Academy of Sciences, July 2016, Wiley

    Bo Abrahamsen

  158. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study

    Article • BMJ, June 2016, BMJ

    Bo Abrahamsen

  159. Low Levels of Hemoglobin at Admission Are Associated With Increased 30-Day Mortality in Patients With Hip Fracture

    Article • Geriatric Orthopaedic Surgery & Rehabilitation, June 2016, SAGE Publications

    Bo Abrahamsen

  160. Temporal trends in the use of antithrombotics at admission

    Article • Acta Orthopaedica, June 2016, Taylor & Francis

    Bo Abrahamsen

  161. Real-Life and RCT Participants: Alendronate Users Versus FITs’ Trial Eligibility Criterion

    Article • Calcified Tissue International, April 2016, Springer Science + Business Media

    Bo Abrahamsen, Peter Schwarz

  162. Risk of fracture in adults on renal replacement therapy: a Danish national cohort study

    Article • Nephrology Dialysis Transplantation, April 2016, Oxford University Press (OUP)

    Bo Abrahamsen

  163. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Non-sponsored Symposia Abstracts

    Article • Osteoporosis International, April 2016, Springer Science + Business Media

    Bo Abrahamsen

  164. Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population-Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications

    Article • Journal of Bone and Mineral Research, February 2016, Wiley

    Bo Abrahamsen

  165. The epidemiology of fractures in Denmark in 2011

    Article • Osteoporosis International, February 2016, Springer Science + Business Media

    Bo Abrahamsen

  166. The Duration and Safety of Osteoporosis Treatment

    Article • January 2016, Springer Science + Business Media

    Bo Abrahamsen

  167. Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study

    Article • Journal of Bone and Mineral Research, January 2016, Wiley

    Bo Abrahamsen

  168. Abstracts

    Article • European Thyroid Journal, January 2016, Karger Publishers

    Bo Abrahamsen

  169. Conclusions

    Article • January 2016, Springer Science + Business Media

    Bo Abrahamsen

  170. Bisphosphonate drug holidays: we reap what we sow

    Article • Osteoporosis International, December 2015, Springer Science + Business Media

    Bo Abrahamsen

  171. Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study

    Article • Journal of Bone and Mineral Research, December 2015, Wiley

    Bo Abrahamsen

  172. Risks and Benefits of Bisphosphonate Therapies

    Article • Journal of Cellular Biochemistry, November 2015, Wiley

    Bo Abrahamsen

  173. Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients

    Article • Osteoporosis International, November 2015, Springer Science + Business Media

    Bo Abrahamsen

  174. Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study

    Article • Archives of Osteoporosis, October 2015, Springer Science + Business Media

    Bo Abrahamsen, Peter Schwarz

  175. Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis

    Article • American Journal of Clinical Nutrition, October 2015, Oxford University Press (OUP)

    Bo Abrahamsen

  176. Use of anti-osteoporotic drugs in central Norway after a forearm fracture

    Article • Archives of Osteoporosis, September 2015, Springer Science + Business Media

    Bo Abrahamsen

  177. Bone: Sequential osteoporosis treatment—the order of things

    Article • Nature Reviews Endocrinology, August 2015, Nature

    Bo Abrahamsen

  178. Vitamin D and spontaneous abortion

    Article • American Journal of Clinical Nutrition, July 2015, Oxford University Press (OUP)

    Dr Henrik Thybo Christesen, Bo Abrahamsen

  179. Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data

    Article • Journal of Bone and Mineral Research, May 2015, Wiley

    Bo Abrahamsen

  180. The Excess Risk of Major Osteoporotic Fractures in Hypothyroidism Is Driven by Cumulative Hyperthyroid as Opposed to Hypothyroid Time: An Observational Register-Based Time-Resolved Cohort Analysis

    Article • Journal of Bone and Mineral Research, April 2015, Wiley

    Bo Abrahamsen

  181. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2015, Endocrine Society

    Bo Abrahamsen

  182. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome

    Article • February 2015, Bioscientifica

    Professor Marianne Andersen, Bo Abrahamsen

  183. Denosumab: A novel antiresorptive drug for osteoporosis

    Article • Cleveland Clinic Journal of Medicine, February 2015, Cleveland Clinic Journal of Medicine

    Bo Abrahamsen

  184. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2015): Poster Abstracts

    Article • Osteoporosis International, February 2015, Springer Science + Business Media

    Bo Abrahamsen

  185. Osteoporosis Conference 2014

    Article • Osteoporosis International, October 2014, Springer Science + Business Media

    Bo Abrahamsen

  186. Oral Bisphosphonate Use and Total Knee/Hip Implant Survival: Validation of Results in an External Population-Based Cohort

    Article • Arthritis & Rheumatology, October 2014, Wiley

    Bo Abrahamsen

  187. Duration of Thyroid Dysfunction Correlates with All-Cause Mortality. The OPENTHYRO Register Cohort

    Article • PLOS One, October 2014, PLOS

    Bo Abrahamsen

  188. Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective

    Article • Osteoporosis International, September 2014, Springer Science + Business Media

    Bo Abrahamsen

  189. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures

    Article • BoneKEy Reports, September 2014, Portico

    Bo Abrahamsen, Peter Schwarz

  190. Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients

    Article • Osteoporosis International, August 2014, Springer Science + Business Media

    Bo Abrahamsen, Peter Schwarz

  191. Low Serum Thyrotropin Level and Duration of Suppression as a Predictor of Major Osteoporotic Fractures-The OPENTHYRO Register Cohort

    Article • Journal of Bone and Mineral Research, August 2014, Wiley

    Bo Abrahamsen

  192. Comment on Tadrous et al.: Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis

    Article • Osteoporosis International, July 2014, Springer Science + Business Media

    Bo Abrahamsen

  193. Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

    Article • Bone Abstracts, May 2014, Bioscientifica

    Bo Abrahamsen

  194. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy

    Article • Scandinavian Journal of Urology, February 2014, Taylor & Francis

    Bo Abrahamsen

  195. Status of drug development for the prevention and treatment of osteoporosis

    Article • Expert Opinion on Drug Discovery, February 2014, Informa Healthcare

    Bo Abrahamsen, Peter Schwarz

  196. Women's experiences of their osteoporosis diagnosis at the time of diagnosis and 6 months later: A phenomenological hermeneutic study

    Article • International Journal of Qualitative Studies on Health and Well-Being, January 2014, Taylor & Francis

    Bo Abrahamsen

  197. Response: Is heart failure a debatable end-point for bisphosphonate treatment in an older osteoporotic population?

    Article • Journal of Internal Medicine, November 2013, Wiley

    Bo Abrahamsen

  198. Proton pump inhibitor use and fracture risk — effect modification by histamine H1 receptor blockade. Observational case–control study using National Prescription Data

    Article • Bone, November 2013, Elsevier

    Bo Abrahamsen

  199. Osteoporosis in the European Union: a compendium of country-specific reports

    Article • Archives of Osteoporosis, October 2013, Springer Science + Business Media

    Bo Abrahamsen

  200. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

    Article • Journal of Bone and Mineral Research, October 2013, Wiley

    Bo Abrahamsen

  201. Eliminating the need for fasting with oral administration of bisphosphonates

    Article • Therapeutics and Clinical Risk Management, October 2013, Dove Medical Press

    Bo Abrahamsen

  202. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study

    Article • Bone, September 2013, Elsevier

    Bo Abrahamsen

  203. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate

    Article • Osteoporosis International, August 2013, Springer Science + Business Media

    Bo Abrahamsen

  204. Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review

    Article • Journal of Bone and Mineral Research, July 2013, Wiley

    Bo Abrahamsen

  205. Safety issues with bisphosphonate therapy for osteoporosis

    Article • Rheumatology, July 2013, Oxford University Press (OUP)

    Bo Abrahamsen

  206. Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study

    Article • Clinical Endocrinology, July 2013, Wiley

    Bo Abrahamsen

  207. Heart failure in patients treated with bisphosphonates

    Article • Journal of Internal Medicine, June 2013, Wiley

    Bo Abrahamsen

  208. The bisphosphonates: risks and benefits of long term use

    Article • Current Opinion in Pharmacology, June 2013, Elsevier

    Bo Abrahamsen

  209. The influence of early exposure to vitamin D for development of diseases later in life

    Article • BMC Public Health, May 2013, Springer Science + Business Media

    Bo Abrahamsen

  210. The role of vitamin D supplementation in patients with rheumatic diseases

    Article • Nature Reviews Rheumatology, May 2013, Nature

    Bo Abrahamsen

  211. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial

    Article • Annals of the Rheumatic Diseases, May 2013, BMJ

    Bo Abrahamsen

  212. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases

    Article • Osteoporosis International, April 2013, Springer Science + Business Media

    Bo Abrahamsen

  213. Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted

    Article • BMJ, March 2013, BMJ

    Bo Abrahamsen

  214. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database

    Article • Journal of Bone and Mineral Research, February 2013, Wiley

    Bo Abrahamsen

  215. Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence

    Article • Osteoporosis International, November 2012, Springer Science + Business Media

    Bo Abrahamsen

  216. Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids

    Article • Osteoporosis International, November 2012, Springer Science + Business Media

    Bo Abrahamsen

  217. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study

    Article • Osteoporosis International, October 2012, Springer Science + Business Media

    Bo Abrahamsen

  218. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2012, Endocrine Society

    Bo Abrahamsen

  219. Antidepressant medications and osteoporosis

    Article • Bone, September 2012, Elsevier

    Bo Abrahamsen

  220. Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA)

    Article • Age and Ageing, August 2012, Oxford University Press (OUP)

    Bo Abrahamsen

  221. Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2012, Endocrine Society

    Bo Abrahamsen, Professor David Torgerson

  222. Bisphosphonates and colon cancer: reply

    Article • Osteoporosis International, July 2012, Springer Science + Business Media

    Bo Abrahamsen

  223. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study

    Article • Osteoporosis International, May 2012, Springer Science + Business Media

    Bo Abrahamsen

  224. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT

    Article • Journal of Bone and Mineral Research, May 2012, Wiley

    Bo Abrahamsen

  225. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database

    Article • Osteoporosis International, May 2012, Springer Science + Business Media

    Bo Abrahamsen

  226. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures

    Article • Bone, May 2012, Elsevier

    Bo Abrahamsen

  227. Characteristics of patients who suffer major osteoporotic fractures despite adhering to bisphosphonate treatment: A national prescription register study

    Article • Bone, May 2012, Elsevier

    Bo Abrahamsen

  228. Atypical femur fractures: Refining the clinical picture

    Article • Journal of Bone and Mineral Research, April 2012, Wiley

    Bo Abrahamsen

  229. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

    Article • Osteoporosis International, March 2012, Springer Science + Business Media

    Bo Abrahamsen

  230. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study

    Article • Osteoporosis International, March 2012, Springer Science + Business Media

    Bo Abrahamsen

  231. Disentangling the Emerging Evidence around Atypical Fractures

    Article • Current Rheumatology Reports, February 2012, Springer Science + Business Media

    Bo Abrahamsen

  232. Esophageal and gastric cancer incidence and mortality in alendronate users

    Article • Journal of Bone and Mineral Research, February 2012, Wiley

    Bo Abrahamsen

  233. Osteoporosis and vertebral fractures in men aged 60-74 years

    Article • Age and Ageing, January 2012, Oxford University Press (OUP)

    Bo Abrahamsen

  234. Season of Birth and the Risk of Hip Fracture in Danish Men and Women Aged 65+

    Article • Frontiers in Endocrinology, January 2012, Frontiers

    Bo Abrahamsen

  235. Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low

    Article • Evidence-Based Medicine, October 2011, BMJ

    Bo Abrahamsen

  236. Screening: FRAX® in clinical practice

    Article • Nature Reviews Rheumatology, October 2011, Nature

    Bo Abrahamsen

  237. Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures

    Article • Annals of Internal Medicine, October 2011, American College of Physicians

    Bo Abrahamsen

  238. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research

    Article • Journal of Bone and Mineral Research, July 2011, Wiley

    Bo Abrahamsen

  239. Safety of bisphosphonates

    Article • Bone, July 2011, Elsevier

    Bo Abrahamsen

  240. Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate

    Article • Archives of Internal Medicine, June 2011, American Medical Association (AMA)

    Bo Abrahamsen

  241. Inverse Association Between Duration of Use of Acid-Suppressive Medications and Fracture Risk—Reply

    Article • Archives of Internal Medicine, June 2011, American Medical Association (AMA)

    Bo Abrahamsen

  242. Bone freezing and bisphosphonates

    Article • Maturitas, May 2011, Elsevier

    Bo Abrahamsen

  243. Predictors of adherence to oral bisphosphonate therapy: A register-based national open cohort study

    Article • Bone, May 2011, Elsevier

    Bo Abrahamsen

  244. Do calcium plus vitamin D supplements increase cardiovascular risk?

    Article • BMJ, April 2011, BMJ

    Bo Abrahamsen

  245. Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates

    Article • Scandinavian Journal of Public Health, March 2011, SAGE Publications

    Bo Abrahamsen

  246. Risk factors for fracture in elderly men: a population-based prospective study

    Article • Osteoporosis International, March 2011, Springer Science + Business Media

    Bo Abrahamsen

  247. Pattern of use of DXA scans in men: a cross-sectional, population-based study

    Article • Osteoporosis International, February 2011, Springer Science + Business Media

    Bo Abrahamsen

  248. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2010, Endocrine Society

    Bo Abrahamsen

  249. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

    Article • Journal of Bone and Mineral Research, October 2010, Wiley

    Bo Abrahamsen

  250. Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism

    Article • Clinical Endocrinology, October 2010, Wiley

    Bo Abrahamsen

  251. Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results

    Article • Osteoporosis International, August 2010, Springer Science + Business Media

    Bo Abrahamsen

  252. Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study

    Article • Osteoporosis International, August 2010, Springer Science + Business Media

    Bo Abrahamsen

  253. Bisphosphonate adverse effects, lessons from large databases

    Article • Current Opinion in Rheumatology, July 2010, Wolters Kluwer Health

    Bo Abrahamsen

  254. Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk

    Article • Osteoporosis International, June 2010, Springer Science + Business Media

    Bo Abrahamsen

  255. Subtrochanteric and diaphyseal fractures in patients during long-term alendronate treatment: Expanded and extended national register based cohort study

    Article • Bone, June 2010, Elsevier

    Bo Abrahamsen

  256. Adiponectin and Peak Bone Mass in Men: A Cross-Sectional, Population-Based Study

    Article • Calcified Tissue International, May 2010, Springer Science + Business Media

    Bo Abrahamsen

  257. Adverse Effects of Bisphosphonates

    Article • Calcified Tissue International, April 2010, Springer Science + Business Media

    Bo Abrahamsen

  258. Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study

    Article • Osteoporosis International, February 2010, Springer Science + Business Media

    Bo Abrahamsen

  259. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival

    Article • Age and Ageing, January 2010, Oxford University Press (OUP)

    Bo Abrahamsen

  260. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe

    Article • BMJ, January 2010, BMJ

    Bo Abrahamsen, Professor David Torgerson

  261. Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study

    Article • Journal of Bone and Mineral Research, June 2009, Wiley

    Bo Abrahamsen

  262. Prevention and treatment of osteoporosis in women: an update

    Article • Obstetrics Gynaecology & Reproductive Medicine, June 2009, Elsevier

    Bo Abrahamsen

  263. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006

    Article • Osteoporosis International, May 2009, Springer Science + Business Media

    Bo Abrahamsen

  264. Excess mortality following hip fracture: a systematic epidemiological review

    Article • Osteoporosis International, May 2009, Springer Science + Business Media

    Bo Abrahamsen

  265. Atrial fibrillation in fracture patients treated with oral bisphosphonates

    Article • Journal of Internal Medicine, May 2009, Wiley

    Bo Abrahamsen

  266. More on Reports of Esophageal Cancer with Oral Bisphosphonate Use

    Article • New England Journal of Medicine, April 2009, New England Journal of Medicine (NEJM/MMS)

    Bo Abrahamsen

  267. No Association Between Hip Geometry and Four Common Polymorphisms Associated with Fracture: The Danish Osteoporosis Prevention Study

    Article • Calcified Tissue International, February 2009, Springer Science + Business Media

    Bo Abrahamsen

  268. Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk

    Article • Osteoporosis International, August 2008, Springer Science + Business Media

    Bo Abrahamsen

  269. Changes in bone mineral density (BMD) around the cemented Exeter stem: A prospective study in 18 women with 5 years follow-up

    Article • Acta Orthopaedica, August 2008, Taylor & Francis

    Bo Abrahamsen

  270. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence

    Article • Osteoporosis International, June 2008, Springer Science + Business Media

    Bo Abrahamsen

  271. Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Peak Bone Mass in Non-sedentary Men: Results from the Odense Androgen Study

    Article • Calcified Tissue International, December 2007, Springer Science + Business Media

    Bo Abrahamsen

  272. Fracture risk in Danish men with prostate cancer: a nationwide register study

    Article • BJU International, October 2007, Wiley

    Bo Abrahamsen

  273. Erratum

    Article • Pharmacogenetics and Genomics, September 2007, Wolters Kluwer Health

    Bo Abrahamsen

  274. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross‐sectional study

    Article • Clinical Endocrinology, August 2007, Wiley

    Claus H. Gravholt, Bo Abrahamsen

  275. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment

    Article • Pharmacogenetics and Genomics, July 2007, Wolters Kluwer Health

    Bo Abrahamsen

  276. Population-based reference values for bone mineral density in young men

    Article • Osteoporosis International, May 2007, Springer Science + Business Media

    Bo Abrahamsen

  277. Comment on Schott et al.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model

    Article • Osteoporosis International, March 2007, Springer Science + Business Media

    Bo Abrahamsen

  278. Estimates of fracture probability in Denmark: reply to Johansson et al

    Article • Osteoporosis International, February 2007, Springer Science + Business Media

    Bo Abrahamsen

  279. Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism

    Article • AJP Endocrinology and Metabolism, January 2007, American Physiological Society

    Bo Abrahamsen

  280. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy

    Article • Thrombosis and Haemostasis, January 2007, Schattauer GmbH

    Bo Abrahamsen

  281. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism

    Article • Bone, July 2006, Elsevier

    Bo Abrahamsen

  282. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS)

    Article • Thrombosis and Haemostasis, April 2006, Schattauer GmbH

    Bo Abrahamsen

  283. Ten-Year Absolute Risk of Osteoporotic Fractures According to BMD T Score at Menopause: The Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, February 2006, Wiley

    Bo Abrahamsen

  284. MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men—results from the Odense Androgen Study

    Article • Bone, February 2006, Elsevier

    Bo Abrahamsen, Peter Schwarz

  285. Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study

    Article • Osteoporosis International, September 2005, Springer Science + Business Media

    Bo Abrahamsen

  286. Prevention and treatment of osteoporosis in women

    Article • Current Obstetrics and Gynaecology, August 2005, Elsevier

    Bo Abrahamsen

  287. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study

    Article • BMJ, April 2005, BMJ

    Bo Abrahamsen

  288. Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins

    Article • Bone, April 2005, Elsevier

    Bo Abrahamsen

  289. Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study

    Article • Bone, March 2005, Elsevier

    Bo Abrahamsen

  290. Geometry of the Proximal Femur in Relation to Age and Sex: a Cross-Sectional Study in Healthy Adult Danes

    Article • Acta Radiologica, January 2005, SAGE Publications

    Bo Abrahamsen

  291. Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures

    Article • Calcified Tissue International, November 2004, Springer Science + Business Media

    Bo Abrahamsen

  292. Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry

    Article • Osteoporosis International, September 2004, Springer Science + Business Media

    Bo Abrahamsen

  293. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism

    Article • Bone, July 2004, Elsevier

    Bo Abrahamsen

  294. Response rates to oestrogen treatment in perimenopausal women: 5-year data from The Danish Osteoporosis Prevention Study (DOPS)

    Article • Maturitas, July 2004, Elsevier

    Bo Abrahamsen

  295. Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency

    Article • European Journal of Endocrinology, May 2004, Bioscientifica

    Bo Abrahamsen

  296. Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes—Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy

    Article • Calcified Tissue International, April 2004, Springer Science + Business Media

    Bo Abrahamsen

  297. Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism

    Article • Calcified Tissue International, September 2003, Springer Science + Business Media

    Bo Abrahamsen

  298. Standardization of BMD T-Scores in the First Five Years After the Menopause

    Article • Journal of Clinical Densitometry, June 2003, Elsevier

    Bo Abrahamsen

  299. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study

    Article • Journal of Thrombosis and Haemostasis, May 2003, Wiley

    Bo Abrahamsen

  300. A Common Methylenetetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, April 2003, Wiley

    Bo Abrahamsen

  301. Hormone Replacement Therapy Dissociates Fat Mass and Bone Mass, and Tends to Reduce Weight Gain in Early Postmenopausal Women: A Randomized Controlled 5-Year Clinical Trial of the Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, February 2003, Wiley

    Bo Abrahamsen

  302. Polymorphisms in the CYP19 and AR Genes?Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women With or Without Hormone Replacement Therapy: The Danish Osteoporosis Prevention Study

    Article • Calcified Tissue International, January 2003, Springer Science + Business Media

    Bo Abrahamsen

  303. Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1b and IL-6

    Article • Calcified Tissue International, January 2003, Springer Science + Business Media

    Bo Abrahamsen

  304. Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women

    Article • Calcified Tissue International, November 2002, Springer Science + Business Media

    Bo Abrahamsen

  305. When Should Densitometry Be Repeated in Healthy Peri- and Postmenopausal Women: The Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, November 2002, Oxford University Press (OUP)

    Bo Abrahamsen

  306. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies

    Article • Clinical Endocrinology, August 2002, Wiley

    Bo Abrahamsen

  307. Two Polymorphisms in the Vitamin D Receptor Gene-Association With Bone Mass and 5-Year Change in Bone Mass With or Without Hormone-Replacement Therapy in Postmenopausal Women: The Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, August 2002, Wiley

    Bo Abrahamsen

  308. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: A randomized controlled study

    Article • American Journal of Obstetrics and Gynecology, July 2002, Elsevier

    Bo Abrahamsen

  309. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women

    Article • Maturitas, December 2001, Elsevier

    Bo Abrahamsen

  310. Discordance Between Changes in Bone Mineral Density Measured at Different Skeletal Sites in Perimenopausal Women—Implications for Assessment of Bone Loss and Response to Therapy: The Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, July 2001, Oxford University Press (OUP)

    Bo Abrahamsen

  311. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women — results of the Danish Osteoporosis Prevention Study

    Article • Maturitas, October 2000, Elsevier

    Bo Abrahamsen

  312. Cytokines and Bone Loss in a 5-Year Longitudinal Study-Hormone Replacement Therapy Suppresses Serum Soluble Interleukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study

    Article • Journal of Bone and Mineral Research, August 2000, Wiley

    Bo Abrahamsen

  313. Errata

    Article • Diabetic Medicine, April 2000, Wiley

    Bo Abrahamsen

  314. Correlations between insulin sensitivity and bone mineral density in non-diabetic men

    Article • Diabetic Medicine, February 2000, Wiley

    Bo Abrahamsen, Professor Timothy Charles Skinner

  315. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women

    Article • Bone, February 2000, Elsevier

    Bo Abrahamsen

  316. Vitamin D Receptor Alleles Do Not Predict Bone Mineral Density or Bone Loss in Danish Perimenopausal Women

    Article • Bone, May 1998, Elsevier

    Bo Abrahamsen

  317. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention

    Article • Maturitas, December 1997, Elsevier

    Bo Abrahamsen

  318. Site of Osteodensitometry in Perimenopausal Women: Correlation and Limits of Agreement Between Anatomic Regions

    Article • Journal of Bone and Mineral Research, September 1997, Wiley

    Bo Abrahamsen

  319. Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra

    Article • Bone, March 1997, Elsevier

    Bo Abrahamsen

  320. Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry

    Article • American Journal of Clinical Nutrition, January 1996, Elsevier

    Bo Abrahamsen

  321. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements

    Article • Bone, March 1995, Elsevier

    Bo Abrahamsen

  322. Relevance of Ki-67 expression in the classification of non-Hodgkin's lymphomas: a morphometric and double-immunostaining study

    Article • Histopathology, January 1992, Wiley

    Bo Abrahamsen